TRAIL: a potential agent for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Conventional cancer therapies like chemotherapy and radiation often face challenges due to innate or acquired resistance in cancer cells.
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L) is a key molecule in the TNF ligand family, inducing programmed cell death (apoptosis) via death receptor activation.
• TRAIL demonstrates therapeutic potential as most cancer cells are sensitive to its apoptotic effects, while normal cells exhibit resistance.

Purpose of the Study:

• To review the regulatory mechanisms of TRAIL-induced apoptosis.
• To elucidate the molecular basis for synergistic effects when TRAIL is combined with chemotherapy or irradiation.
• To analyze the potential cytotoxicity of TRAIL as a limiting factor for its clinical application.

Main Methods:

• This review synthesizes existing research on TRAIL-induced apoptosis.
• It examines the molecular pathways involved in TRAIL signaling and cancer cell death.
• The review analyzes studies investigating TRAIL in combination therapies and its safety profile.

Main Results:

• TRAIL effectively induces apoptosis in a majority of cancer cell types.
• Combining TRAIL with chemotherapy or radiation significantly enhances apoptotic outcomes.
• Potential dose-limiting cytotoxicity of TRAIL is a critical consideration for therapeutic development.

Conclusions:

• TRAIL represents a promising therapeutic agent for cancer treatment due to its selective induction of apoptosis in malignant cells.
• Combination strategies involving TRAIL with conventional treatments amplify its anti-cancer efficacy.
• Further research is necessary to optimize TRAIL-based therapies and mitigate potential adverse effects for successful clinical translation.